A Phase I, Open Label, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetic Properties of the Combination of Cilengitide and Paclitaxel in Patients With Advanced Solid Malignancies

Trial Profile

A Phase I, Open Label, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetic Properties of the Combination of Cilengitide and Paclitaxel in Patients With Advanced Solid Malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Cilengitide (Primary) ; Paclitaxel
  • Indications Adenocarcinoma; Advanced breast cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Jun 2017 Results published in the Cancer Chemotherapy and Pharmacology
    • 14 Mar 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 14 Mar 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top